Home > Insider Trading > Filing (0000899243-21-010463)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1815442	Kymera Therapeutics Inc.	KYMR	Biological Products, (No Disgnostic Substances) (2836)	812992166

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1821074	N. Bruce Jacobs	C/O Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown MA 02472	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-08	10,000	$2.08	10,000	No	4	M	Direct
Common Stock	Disposition	2021-03-08	7,699	$50.46	2,301	No	4	S	Direct
Common Stock	Disposition	2021-03-08	2,300	$51.28	1	No	4	S	Direct
Common Stock	Disposition	2021-03-08	1	$52.15	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-08	10,000	$0.00	10,000	$2.08

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
244,061		2030-08-19	No	4	M	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.